Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
376 hedge funds and large institutions have $6.62B invested in Intra-Cellular Therapies Inc. in 2024 Q2 according to their latest regulatory filings, with 76 funds opening new positions, 143 increasing their positions, 127 reducing their positions, and 43 closing their positions.
77% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 43
13% more repeat investments, than reductions
Existing positions increased: 143 | Existing positions reduced: 127
9% more funds holding
Funds holding: 346 → 376 (+30)
8% more capital invested
Capital invested by funds: $6.15B → $6.62B (+$469M)
9% more call options, than puts
Call options by funds: $28.9M | Put options by funds: $26.5M
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
Top Buyers
| 1 |
JP Morgan Chase
New York
|
+$116M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$79.2M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$72.3M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$59.9M |
| 5 |
PA
Perceptive Advisors
New York
|
+$45.8M |
Top Sellers
| 1 |
BlackRock
New York
|
-$122M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$31.3M |
| 3 |
State Street
Boston,
Massachusetts
|
-$30.4M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$28.4M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$26.3M |
ITCI Hedge Fund Activity: Q2 2024 in Review
376 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2024, worth a combined $6.62B — up 7.6% from $6.15B a quarter earlier.
Buyers outnumbered sellers: 76 funds opened new ITCI positions and 43 closed out — a net gain of 33 holders — while 143 added to existing stakes and 127 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $116M. The largest seller was BlackRock, cutting an estimated $122M.
- 376 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2024, up from 346 in Q1 2024.
- Funds reported $6.62B of Intra-Cellular Therapies Inc. stock for Q2 2024, up 7.6% quarter-over-quarter.
- 76 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2024 and 43 closed out, a net change of +33 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q2 2024 was JP Morgan Chase, an estimated $116M added.
- The largest Intra-Cellular Therapies Inc. seller in Q2 2024 was BlackRock, an estimated $122M sold.
Based on aggregated 13F filings for Q2 2024.